中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2010年
11期
743-746
,共4页
陈健%张旭%田茹%刘艺%董红梅%郭瑞峰%梁化印
陳健%張旭%田茹%劉藝%董紅梅%郭瑞峰%樑化印
진건%장욱%전여%류예%동홍매%곽서봉%량화인
乳腺肿瘤%癌,导管,乳腺%受体,雄激素%诊断%治疗
乳腺腫瘤%癌,導管,乳腺%受體,雄激素%診斷%治療
유선종류%암,도관,유선%수체,웅격소%진단%치료
Breast neoplasms%Carcinoma,ductal,breast%Receptor,androgens%Diagnosis%Therapy,adjuvant
目的 研究雄激素受体(AR)在乳腺浸润性导管癌中的表达及其与雌激素受体(ER)、孕激素受体(PR)和HER2状态的关系,探讨其作为乳腺癌治疗靶点的可行性.方法 采用免疫组织化学EnVision法检测AR、ER、PR、HER2在175例乳腺浸润性导管癌中的表达,依据结果分为腺腔A型、腺腔B型、HER2过表达型和三阴性型(ER-/PR-/HER2-)组.结果 175例中AR阳性88例(50.3%),AR表达与ER、PR、HER2均呈正相关(P＜0.01).腺腔A型53例(30.3%),腺腔B型33例(18.9%),HER2过表达型23例(13.1%),三阴性型66例(37.7%),AR阳性率分别为56.6%(30/53),75.8%(25/33)、47.8%(11/23)和33.3%(22/66),组间AR阳性率差异显著(x2=17.054,P=0.001).三阴性型组AR阳性者核分裂象较少(x2=5.140,P=0.023),腺腔A型组AR阳性者多为年轻患者(x2=4.567,P=0.033),差异有统计学意义.其他组内AR表达与否和临床病理学特征比较无统计学意义.结论 AR在乳腺癌中有较高的阳性率,可作为乳腺癌,特别是三阴性型乳腺癌的治疗靶点.
目的 研究雄激素受體(AR)在乳腺浸潤性導管癌中的錶達及其與雌激素受體(ER)、孕激素受體(PR)和HER2狀態的關繫,探討其作為乳腺癌治療靶點的可行性.方法 採用免疫組織化學EnVision法檢測AR、ER、PR、HER2在175例乳腺浸潤性導管癌中的錶達,依據結果分為腺腔A型、腺腔B型、HER2過錶達型和三陰性型(ER-/PR-/HER2-)組.結果 175例中AR暘性88例(50.3%),AR錶達與ER、PR、HER2均呈正相關(P＜0.01).腺腔A型53例(30.3%),腺腔B型33例(18.9%),HER2過錶達型23例(13.1%),三陰性型66例(37.7%),AR暘性率分彆為56.6%(30/53),75.8%(25/33)、47.8%(11/23)和33.3%(22/66),組間AR暘性率差異顯著(x2=17.054,P=0.001).三陰性型組AR暘性者覈分裂象較少(x2=5.140,P=0.023),腺腔A型組AR暘性者多為年輕患者(x2=4.567,P=0.033),差異有統計學意義.其他組內AR錶達與否和臨床病理學特徵比較無統計學意義.結論 AR在乳腺癌中有較高的暘性率,可作為乳腺癌,特彆是三陰性型乳腺癌的治療靶點.
목적 연구웅격소수체(AR)재유선침윤성도관암중적표체급기여자격소수체(ER)、잉격소수체(PR)화HER2상태적관계,탐토기작위유선암치료파점적가행성.방법 채용면역조직화학EnVision법검측AR、ER、PR、HER2재175례유선침윤성도관암중적표체,의거결과분위선강A형、선강B형、HER2과표체형화삼음성형(ER-/PR-/HER2-)조.결과 175례중AR양성88례(50.3%),AR표체여ER、PR、HER2균정정상관(P＜0.01).선강A형53례(30.3%),선강B형33례(18.9%),HER2과표체형23례(13.1%),삼음성형66례(37.7%),AR양성솔분별위56.6%(30/53),75.8%(25/33)、47.8%(11/23)화33.3%(22/66),조간AR양성솔차이현저(x2=17.054,P=0.001).삼음성형조AR양성자핵분렬상교소(x2=5.140,P=0.023),선강A형조AR양성자다위년경환자(x2=4.567,P=0.033),차이유통계학의의.기타조내AR표체여부화림상병이학특정비교무통계학의의.결론 AR재유선암중유교고적양성솔,가작위유선암,특별시삼음성형유선암적치료파점.
Objective To investigate the expression of androgen receptor (AR) in breast carcinoma and its relationship with estrogen receptor (ER), progesterone receptor (PR) and HER2 status, and to discuss its potential as treatment target. Methods Immunohistochemical method was used to detect AR, ER, PR and HER2 expression in 175 cases of invasive ductal carcinoma of breast, which were divided into four groups: luminal A, luminal B, HER2- overexpression and triple negative group. Results Eighty-eight cases (50.3%) were AR positive in 175 cases, the expression of AR was positively correlated with ER, PR and HER2 status. All the cases were grouped as follows: 53 cases (30.3%) were luminal A, 33 cases (18.9%) were luminal B, 23 cases (13.1%) were HER2- overexpression and 66 cases (37.7%) were triple negative, the AR expression rate was 56.6% (30/53), 75.8% (25/33), 47.8% (11/23), 33.3% (22/66), respectively. There was significant difference among the four groups' AR expression rates. With respect to the clinico-pathological features, AR positive cases were younger in luminal A and had lower mitosis rate in triple negative subgroups than the negative cases (x2 = 4.567, P = 0.033; x2 = 5.140, P =0.023, respectively). Conclusion AR has a high positive rate in breast carcinoma, and may be an ideal therapeutic target for breast carcinoma, especially for the triple negative subtype.
